What development phase is IPODATE SODIUM in?

IPODATE SODIUM is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IPODATE SODIUM

FDA-approved approved Small molecule Quality 1/100

Ipodate Sodium is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	IPODATE SODIUM
Modality	Small molecule
Phase	FDA-approved
First approval	1962

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IPODATE SODIUM CI brief — competitive landscape report
IPODATE SODIUM updates RSS · CI watch RSS